The financials
Alamar Biosciences, Inc. by the numbers
Alamar Biosciences, Inc. (ALMR) reported revenue of $29M in Q2 2026 (quarter ended June 30, 2026), up 125% from the same quarter a year earlier. That came with a gross margin of 60% and net loss of $13M. Its largest product in 2026-Q2 was Consumables at $15M, 53% of the disclosed total, just ahead of Instruments at 26%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $29M | $13M | +125% |
| Gross profit | $18M | $6.4M | +177% |
| Operating income | −$14M | −$8.6M | n/a |
| Net income | −$13M | −$7.7M | n/a |
| Diluted EPS | −$0.22 | −$0.68 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Consumables | $15M | 53% |
| Instruments | $7.8M | 26% |
| Service | $6.2M | 21% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $29.4M (+13%)
Segment Latestquarter on quarteryear on year
- Consumables$15.5M$15.5MQoQ +11%year on year +147%+11%+147%
- Instruments$7.8M$7.8MQoQ +5.5%year on year +35%+5.5%+35%
- Service$6.2M$6.2MQoQ +31%year on year +49%+31%+49%
Medical Devices
The closest names by size in the same industry